OIG reports released on June 11, 2026, pulled back the curtain on how Medicare Advantage (MA) plans handle prior authorization for long-term care hospital (LTCH) and inpatient rehabilitation facility (IRF) stays — and the numbers are stark. The three largest MA plans by enrollment — UnitedHealthcare, Humana, and CVS/Aetna — denied between 71% and 80% of these high-acuity post-acute care requests, compared to a peer average of just 42%. For nurses working in SNFs, LTCHs, and IRFs, those statistics represent a daily reality: hours spent battling approvals for care that patients are legally entitled to receive.
The OIG's Office of Evaluation and Inspections examined prior authorization data from 2022–2023, looking specifically at two categories of inpatient post-acute care that require intensive clinical justification. Long-term care hospitals provide extended, hospital-level care to medically complex patients — ventilator-dependent patients, wound care cases, complex infectious disease — who need more than a traditional acute stay but aren't ready for a skilled nursing or rehabilitation setting. Inpatient rehabilitation facilities deliver intensive physical, occupational, and speech therapy for patients recovering from strokes, amputations, major joint replacements, and traumatic injuries. Both require prior authorization under most MA plans, and both showed denial rates that the OIG flagged as patterns warranting regulatory attention.
What the Numbers Mean for Nurses
For nurses in long-term acute care settings, the denial dynamic is familiar — but it is now documented with federal authority behind it. The typical workflow when an MA plan denies a LTCH or IRF admission looks like this: a case manager or unit RN contacts the utilization review department, which reaches the insurer, which assigns a physician reviewer — often without board certification in the relevant specialty — who issues a denial. Then comes the appeal process. Sometimes the appeal is handled at the bedside clinical team level. Sometimes it escalates to an Administrative Law Judge.
The OIG found that 36% of LTCH denials and 43% of IRF denials were overturned on appeal. That means more than a third of patients who were denied and fought back received a ruling that their original denial was incorrect. Patients who gave up, accepted a lower level of care, or went home because they couldn't navigate the appeals process never received care their physicians recommended.
That 36–43% overturn rate is federal documentation that a substantial fraction of these denials were medically unjustified when they were issued. It is not a reflection of changing clinical circumstances during the appeal period — it is a retrospective finding that the initial decision was wrong.
The Three Plans Under the Microscope
The OIG examined prior authorization denial rates for LTCH and IRF requests across the largest MA plans and found a clear spread between the major plans and their peers:
| Plan | LTCH/IRF Denial Rate |
|---|---|
| UnitedHealthcare | 71% |
| Humana | 72% |
| CVS/Aetna | 80% |
| Peer Group Average | 42% |
To be precise: all MA plans deny some share of requests, and not every clinical request is fully warranted. But when the three largest plans deny at nearly twice the peer average — and when more than a third of those denials are overturned on appeal — the OIG characterized it as a systemic pattern, not random variation. The reports note that the three plans collectively cover roughly 47% of all Medicare Advantage enrollees, meaning their denial behavior shapes the post-acute experience for tens of millions of patients.
CMS Has Known — and Has Acted Slowly
CMS has been on notice about MA prior authorization problems for years. The agency issued a major final rule in 2024 (CMS-4201-F) requiring MA plans to use clinical criteria consistent with traditional Medicare, respond to urgent prior authorization requests within 72 hours, and provide written explanations for denials that cite specific clinical criteria. That rule was supposed to narrow the gap between MA and traditional Medicare coverage decisions.
The OIG's June 2026 reports suggest that gap remains wide in post-acute care. LTCH and IRF stays are exactly the kind of high-cost, high-need services where MA plans have financial incentive to deny first and approve on appeal — because a meaningful percentage of patients never file an appeal. The OIG's data confirms that MA plans are exploiting that gap.
What the OIG Recommends
The June 11 reports include several specific recommendations directed at CMS:
- Require MA plans to report denial rates by category of care — broken out for LTCH, IRF, and SNF at the plan level — so beneficiaries and researchers can compare plans before enrollment.
- Increase contractor audit frequency for plans with denial rates significantly above the peer average, with particular scrutiny on plans where appeal overturn rates exceed 30%.
- Mandate use of CMS-approved clinical criteria for LTCH and IRF determinations, prohibiting MA plans from using proprietary criteria not validated against traditional Medicare standards.
CMS has not yet issued a formal response to the June 11 reports. The agency typically has 30–90 days to respond officially to OIG recommendations, and has historically concurred with the majority of OIG recommendations in the MA prior authorization space.
What This Means if You Work in Post-Acute Care
For nurses in SNF, LTCH, IRF, or any post-acute setting, this OIG reporting matters in practical terms. Prior authorization denials generate documentation burden that falls on the clinical team — case managers, charge nurses, and unit nurses who spend time on hold, gathering notes, and drafting appeals instead of providing direct care.
The pattern the OIG documented — high denial rates, high appeal overturn rates, and documented deviation from traditional Medicare standards — represents the clearest federal signal yet that MA oversight is heading toward stricter enforcement. For nurses who have watched post-acute beds sit empty because an MA plan denied a transfer that was clinically appropriate, these reports are the federal documentation that confirms: the denial pattern was not a clinical judgment. It was a business model.
The political environment for enforcement is uncertain — the current legislative session has focused on Medicaid cuts, and MA reform is not a near-term congressional priority. But the OIG reports create a paper trail that CMS auditors and state attorneys general can act on. Watch for CMS's formal response later this summer, which will indicate whether the agency is prepared to use its audit and sanction authority against plans with denial rates well above the peer average.